Ortivus AB (publ) (ORTI-B.ST)
SEK 1.48
(-6.62%)
SEK 1.48
(-6.62%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -14.92 Million SEK | -240.37% |
| 2022 | 8.6 Million SEK | -34.44% |
| 2021 | 11.28 Million SEK | -8.28% |
| 2020 | 13.05 Million SEK | 262.9% |
| 2019 | -8.54 Million SEK | -70.97% |
| 2018 | -4.97 Million SEK | -1209.21% |
| 2017 | -387 Thousand SEK | -102.83% |
| 2016 | 13.58 Million SEK | 38.63% |
| 2015 | 9.69 Million SEK | 29.93% |
| 2014 | 7.46 Million SEK | 169.04% |
| 2013 | -10.81 Million SEK | -307.27% |
| 2012 | 5.21 Million SEK | 122.89% |
| 2011 | -22.77 Million SEK | 29.62% |
| 2010 | -23.43 Million SEK | -83.67% |
| 2009 | -17.61 Million SEK | -298.31% |
| 2008 | 8.88 Million SEK | 117.18% |
| 2007 | -30.93 Million SEK | 58.71% |
| 2006 | -125.23 Million SEK | -663.0% |
| 2005 | -16.41 Million SEK | -209.05% |
| 2004 | 24.52 Million SEK | 3.18% |
| 2003 | 14.58 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -828 Thousand SEK | 17.51% |
| 2024 Q2 | -7.19 Million SEK | -676.04% |
| 2023 Q3 | -11.04 Million SEK | -136.32% |
| 2023 Q1 | 494 Thousand SEK | 63.04% |
| 2023 FY | - SEK | -240.37% |
| 2023 Q4 | -713 Thousand SEK | 93.54% |
| 2023 Q2 | -4.67 Million SEK | -1045.75% |
| 2022 Q1 | 1.99 Million SEK | 17.24% |
| 2022 Q2 | 3.49 Million SEK | 74.99% |
| 2022 Q3 | 47 Thousand SEK | -98.66% |
| 2022 Q4 | 303 Thousand SEK | 544.68% |
| 2022 FY | - SEK | -34.44% |
| 2021 Q3 | 2.73 Million SEK | -13.66% |
| 2021 Q2 | 3.17 Million SEK | 83.03% |
| 2021 FY | - SEK | -8.28% |
| 2021 Q1 | 1.73 Million SEK | -21.42% |
| 2021 Q4 | 1.7 Million SEK | -37.71% |
| 2020 Q3 | 1.23 Million SEK | -82.13% |
| 2020 Q1 | 1.11 Million SEK | 164.22% |
| 2020 Q2 | 6.88 Million SEK | 519.53% |
| 2020 FY | - SEK | 262.9% |
| 2020 Q4 | 2.2 Million SEK | 79.19% |
| 2019 Q4 | -1.73 Million SEK | 48.06% |
| 2019 FY | - SEK | -70.97% |
| 2019 Q3 | -3.33 Million SEK | 27.14% |
| 2019 Q2 | -4.57 Million SEK | 21.69% |
| 2019 Q1 | -5.83 Million SEK | -52.95% |
| 2018 FY | - SEK | -1209.21% |
| 2018 Q1 | -3.64 Million SEK | -89.58% |
| 2018 Q2 | -4.54 Million SEK | -24.73% |
| 2018 Q3 | -945 Thousand SEK | 79.19% |
| 2018 Q4 | -3.81 Million SEK | -303.92% |
| 2017 Q4 | -1.92 Million SEK | 47.57% |
| 2017 Q3 | -3.66 Million SEK | -34.14% |
| 2017 Q2 | -2.73 Million SEK | -27.87% |
| 2017 Q1 | -2.13 Million SEK | -248.47% |
| 2017 FY | - SEK | -102.83% |
| 2016 Q1 | -4.49 Million SEK | -205.5% |
| 2016 FY | - SEK | 38.63% |
| 2016 Q4 | 1.43 Million SEK | 96.99% |
| 2016 Q3 | 730 Thousand SEK | 126.25% |
| 2016 Q2 | -2.78 Million SEK | 38.16% |
| 2015 Q2 | 132 Thousand SEK | -74.62% |
| 2015 Q3 | -4.71 Million SEK | -3669.7% |
| 2015 Q1 | 520 Thousand SEK | 114.15% |
| 2015 Q4 | -1.47 Million SEK | 68.76% |
| 2015 FY | - SEK | 29.93% |
| 2014 Q1 | 1.86 Million SEK | 127.29% |
| 2014 FY | - SEK | 169.04% |
| 2014 Q3 | 1.9 Million SEK | 19.86% |
| 2014 Q4 | -3.67 Million SEK | -292.66% |
| 2014 Q2 | 1.59 Million SEK | -14.69% |
| 2013 Q3 | -2.39 Million SEK | 19.12% |
| 2013 Q4 | -6.83 Million SEK | -185.3% |
| 2013 FY | - SEK | -307.27% |
| 2013 Q1 | -1.81 Million SEK | -10.15% |
| 2013 Q2 | -2.96 Million SEK | -63.41% |
| 2012 Q2 | 3.35 Million SEK | 208.64% |
| 2012 FY | - SEK | 122.89% |
| 2012 Q1 | -3.08 Million SEK | 73.67% |
| 2012 Q3 | 3.55 Million SEK | 5.93% |
| 2012 Q4 | -1.64 Million SEK | -146.27% |
| 2011 Q2 | -11.94 Million SEK | -139.11% |
| 2011 Q3 | -8.99 Million SEK | 24.64% |
| 2011 Q4 | -11.73 Million SEK | -30.37% |
| 2011 FY | - SEK | 29.62% |
| 2011 Q1 | -4.99 Million SEK | -23.4% |
| 2010 Q2 | -9.63 Million SEK | -16.29% |
| 2010 Q3 | -10.39 Million SEK | -7.94% |
| 2010 FY | - SEK | -83.67% |
| 2010 Q4 | -4.04 Million SEK | 61.08% |
| 2010 Q1 | -8.28 Million SEK | 0.0% |
| 2009 FY | - SEK | -298.31% |
| 2008 FY | - SEK | 117.18% |
| 2007 FY | - SEK | 58.71% |
| 2006 FY | - SEK | -663.0% |
| 2005 FY | - SEK | -209.05% |
| 2004 FY | - SEK | 3.18% |
| 2003 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AddLife AB (publ) | 1.54 Billion SEK | 100.965% |
| Biotage AB (publ) | 432 Million SEK | 103.455% |
| Bonesupport Holding AB (publ) | 28.93 Million SEK | 151.581% |
| Doxa AB (publ) | 296 Million SEK | 105.043% |
| Elekta AB (publ) | 3.29 Billion SEK | 100.454% |
| iZafe Group AB (publ) | -15.61 Million SEK | 4.425% |
| Ortivus AB (publ) | -14.92 Million SEK | -0.0% |
| Q-linea AB (publ) | -210.98 Million SEK | 92.926% |
| S2Medical AB (publ) | -13.52 Million SEK | -10.325% |
| Synsam AB (publ) | 1.71 Billion SEK | 100.872% |